Nutriband Inc. (NTRB)
- Previous Close
4.0400 - Open
4.1900 - Bid 3.0300 x 200
- Ask 5.0000 x 200
- Day's Range
3.9100 - 4.3900 - 52 Week Range
1.5300 - 5.9270 - Volume
26,044 - Avg. Volume
43,961 - Market Cap (intraday)
33.247M - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6700 - Earnings Date Apr 24, 2024 - Apr 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
nutriband.comRecent News: NTRB
Performance Overview: NTRB
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NTRB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NTRB
Valuation Measures
Market Cap
34.69M
Enterprise Value
35.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.39
Price/Book (mrq)
6.07
Enterprise Value/Revenue
17.08
Enterprise Value/EBITDA
-7.27
Financial Highlights
Profitability and Income Statement
Profit Margin
-253.02%
Return on Assets (ttm)
-32.06%
Return on Equity (ttm)
-68.43%
Revenue (ttm)
2.09M
Net Income Avi to Common (ttm)
-5.28M
Diluted EPS (ttm)
-0.6700
Balance Sheet and Cash Flow
Total Cash (mrq)
1.27M
Total Debt/Equity (mrq)
39.47%
Levered Free Cash Flow (ttm)
-1.92M
Research Analysis: NTRB
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell